A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520117-50-00

Acronym

IMG-007-203

Enrollment

132

Registered

2025-09-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

Mean percent change from baseline in EASI at Week 20

Detailed description

• Mean percent change from baseline in EASI at Week 16, • Proportion of participants achieving a ≥ 75% reduction in EASI (EASI-75) at Week 16 and Week 20, respectively, • Proportion of participants achieving a vIGA-AD score of 0 (clear) or 1 (almost clear) and a ≥ 2-point reduction from baseline at Week 16 and Week 20, respectively, • Incidence and severity of TEAE including treatment-emergent SAEs

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Mean percent change from baseline in EASI at Week 20	—

Secondary

Measure	Time frame
• Mean percent change from baseline in EASI at Week 16, • Proportion of participants achieving a ≥ 75% reduction in EASI (EASI-75) at Week 16 and Week 20, respectively, • Proportion of participants achieving a vIGA-AD score of 0 (clear) or 1 (almost clear) and a ≥ 2-point reduction from baseline at Week 16 and Week 20, respectively, • Incidence and severity of TEAE including treatment-emergent SAEs	—

Measure

Time frame

—

Countries

Czechia, Germany, Hungary, Poland, Spain

Outcome results